Nanobody Specialist Ablynx Bags Global IL-6R Deal With AbbVie
This article was originally published in The Pink Sheet Daily
Executive Summary
Ablynx stands to get $840 million and double-digit royalties under a global license deal with AbbVie to develop and commercialize the Belgian group’s anti-IL-6R candidate ALX-0061 to treat inflammatory diseases. The transaction brings a big boost to the biotech’s prospects.
You may also be interested in...
Start-Up Quarterly Statistics, Q3 2013
Start-up fundraising for Q3 2013 totaled $559.4 million, down from last quarter’s big rally ($907.2 million) but still up from the sluggish first quarter ($398.7 million). More than half of that money went to biopharma companies, a group which also received investments through alliances with equity provisions.
Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug
As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.